A smart wearable solution providing on-the-go monitoring and treatment for DVT patients
SCROLL TO EXPLORE
KinAptic’s mission is to save lives by preventing deadly blood clots in the lower legs by providing an affordable treatment and diagnostics benefit for the patient, clinician, and the payor. The KinAptic technology uses neuromuscular electrical stimulation to activate the human body’s own blood plump to prevent deep vein thrombosis.
Combined with the integrated biometric sensors, KinAptic’s technology allows for the detection, treatment, and tracking of thrombotic conditions. The KinAptic e-wrap enables a portable solution that will improve patient outcomes and lower healthcare costs.
Deep vein thrombosis (DVT) is one of the largest causes of mortality in hospitals in patients admitted with another diagnosis and is often referred to as the “silent killer”. More than 100,000 Americans die of DVT and subsequent pulmonary embolisms (PE) and there are four times more DVT/PE incidences than breast cancer each year.
Current and legacy treatment systems consist of largely ineffective passive treatment devices, cumbersome sequential compression devices limited to hospitals, or expensive pharmaceutical treatments with their own risks of complications.
The KinAptic e-wrap uses neuromuscular electrical stimulation (NMES) to activate the calf muscles, the body’s natural pump that returns blood from the lower legs to the heart. The integrated biometric sensors detect and log data for remote patient monitoring allowing care-givers access to treatment efficacy and patient wellbeing. AI and ML utilize this data for improving the treatment applied to the individual and to help determine best practices from data aggregated from a population of patients.
KinAptic is positioned as both a post-operative treatment for high risk patients of DVT such as bedridden patients with COVID or patients with hip or knee arthroplasty, but also as a perioperative solution. With the integration of biometric sensors, caregivers will be able to monitor a host of inputs from temperature, to swelling, to muscle activity.
Medical costs for the prevention and management of thrombosis is expected to reach $36.7 billion by 2023. More than 100,000 Americans die of DVT and subsequent pulmonary embolisms (PE) and there are four times more DVT/PE incidences than breast cancer each year.
CEO: John Daniels Co-Founder: Joseph Curio Co-Founder: Mark Day